

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1 1. (Original) An antibody that comprises at least one amino acid sequence as
2 listed in SEQ ID NOs:1-8 which can bind to Factor IX/Factor IXa and increase the
3 procoagulation activity of FIXa.
- 1 2. (Original) The antibody according to claim 1, wherein the antibody
2 comprises at least one complement determining region (CDR), the at least one CDR comprising
3 at least one amino acid sequence as listed in SEQ ID NOs:3-8.
- 1 3. (Original) The antibody according to claim 2, wherein the antibody
2 comprises at least three CDRs (CDR1, CDR2 and CDR3) that are embedded in four framework
3 regions, wherein one or more of the at least three CDRs comprise an amino acid sequence as
4 listed in SEQ ID NOs: 3 to 8.
- 1 4. (Original) The antibody according to claim 3, wherein the antibody
2 comprises one or more CDR3, each CDR3 comprising an amino acid sequence selected from the
3 group consisting of SEQ ID NOs: 5 and 8.
- 1 5. (Original) The antibody according to claim 3, wherein CDR1, CDR2 and
2 CDR3 each comprise an amino acid sequence selected from the group consisting of SEQ ID
3 NOs: 3-5.
- 1 6. (Original) The antibody according to claim 3, wherein CDR1, CDR2 and
2 CDR3 each comprise an amino acid sequence selected from the group consisting of SEQ ID
3 NOs: 6-8.

1 7. (Original) The antibody according to claim 2, wherein the antibody
2 comprises at least one of the amino acid sequences listed in SEQ ID NOs: 1-2.

1 8. (Original) The antibody according to claim 7, wherein the antibody
2 comprises both of the amino acid sequences listed in SEQ ID NOs:1-2.

1 9. (Original) The antibody according to claim 1, which is an IgG antibody.

1 10. (Original) The antibody according to claim 1, which is a monoclonal
2 antibody.

1 11. (Original) The antibody according to claim 1, which is an antibody
2 fragment.

1 12. (Original) The antibody according to claim 1, which is a recombinant
2 antibody.

1 13. (Original) The antibody according to claim 12, which is a single chain
2 antibody.

1 14. (Original) The antibody according to claim 1, which is a humanized
2 antibody.

1 15. (Original) The antibody of claim 1, wherein the antibody is labeled.

1 16-21. (Canceled)

1 22. (Original) A pharmaceutical composition comprising an antibody of
2 claim 1 and a pharmaceutically acceptable carrier and/or diluent.

1 23. (Original) The pharmaceutical composition of claim 22, wherein the
2 antibody comprises at least one complement determining region (CDR), the at least one CDR
3 comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.

1 24. (Original) The pharmaceutical composition according to claim 23, further
2 comprising factor IX, factor IXa, factor IXa and/or factor IX.

1 25-27. (Canceled)